9823 Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

9823 Capital’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,429	Closed	-$173K	–	74
2025 Q4	$173K	Buy	+10,429	New	+$149K	0.12%	57

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

9823 Capital's PHAT Position: Q1 2026 in Review

9823 Capital sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 10,429 shares — an estimated $173K sold.

9823 Capital first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $173K in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

9823 Capital reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 10,429 Phathom Pharmaceuticals shares in Q1 2026, an estimated $173K.
9823 Capital first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
9823 Capital's Phathom Pharmaceuticals position peaked at $173K in Q4 2025.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.